Pre Market

Pre-Market Biotech Movers: Data, Deals and Listing Risk Set the Tone
Pre Market

Pre-Market Biotech Movers: Data, Deals and Listing Risk Set the Tone

Pre-market trading on 1 October 2026 rewarded biotech and pharma companies with measured evidence or contracted certainty—biomarker data, signed payments, resolved compliance issues—while projections and modelled risk drew muted responses. Six names moved on verifiable milestones, revealing how investors price conviction in early-stage science and pipeline strategy.

One Court Ruling Wiped 57% Off Liquidia. Who Else Is Exposed?
Healthcare Stocks

One Court Ruling Wiped 57% Off Liquidia. Who Else Is Exposed?

On 30 September 2026, a Delaware patent ruling reshuffled $6 billion in market value between two pulmonary hypertension drugmakers, while early-stage clinical data and capital raises tested biotech valuations across intellectual property, clinical evidence and funding. Six stocks moved on legal exposure, trial results and financing terms—revealing how investors price risk differently across the sector.

FDA Calendar September 2026: PDUFA Dates, First-in-Class Drugs & Biotech Stocks to Watch
Healthcare Stocks

FDA Calendar September 2026: PDUFA Dates, First-in-Class Drugs & Biotech Stocks to Watch

September could be a decisive month for biotech investors. The FDA faces a crowded calendar of PDUFA decisions, first-in-class therapies and a landmark advisory-panel review. From gene therapy and rare diseases to oncology and diagnostics, the outcomes could reshape valuations across a group of closely watched biotech stocks.

The One Company That Quietly Owns the Future – Google
Stocks

The One Company That Quietly Owns the Future – Google

Google (Alphabet) is not just a search company. From YouTube and AI to cloud, self-driving cars, and hidden venture bets, discover why $GOOGL may be the most diversified long-term play on the future of technology